Allergan profit falls as Botox sales slump

By Staff Writers
Thursday, 28 April, 2005

Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.

First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.

Net sales rose to $527 million, from $472 million in the year earlier period.

Botox sales were $176 million, about $10 million short of analyst views.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd